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Mdm2 regulates the stability, translation, subcellular localization and transcriptional activity of p53
protein. Mdm2-dependent p53 inhibition is essential in regulating p53 activity during embryonic
development and in adult tissues. MdmX, an Mdm2 homolog, is also essential for p53 inhibition
in vivo. Recent advances in the ﬁeld from biochemical and genetic studies have revealed an essential
role for the MdmX RING domain in Mdm2-dependent p53 polyubiquitination and degradation.
Mdm2 on its own is a monoubiquitin E3 ligase for p53, but is converted to a p53 polyubiquitin E3
ligase by MdmX through their RING–RING domain interactions. MdmX acts as an activator as well
as a substrate of Mdm2/MdmX E3 complex. The insufﬁciency of Mdm2 for p53 polyubiquitination
also demands other p53 E3 ligases or E4 factors be incorporated into the p53 degradation arena.
Deubiquitinases nullify the effects of E3 actions and reverse the ubiquitination process, which per-
mits a diverse and dynamic pattern of p53 stability control. Unsurprisingly, stress signals target
MdmX to disengage the p53/Mdm2 feedback loop for timely and appropriate p53 responses to these
stresses.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Background: the tumor suppressor p53
p53 suppresses tumor development through multiple activities
including induction of growth arrest, apoptosis, senescence, and
autophagy [1,2]. Beyond tumor suppression, p53 also regulates
fecundity, metabolism, quiescence, and aging [3–8]. p53 remains
dormant in unstressed cells owing to its inherent instability via
fast degradation mechanisms. However, the short-lived p53 pro-
tein is stabilized and activated by many types of abnormal condi-
tions including genotoxic stress, non-genotoxic such as hypoxia,
low pH, heat shock and ribosomal stress, and by aberrant growth
signals, among others [8–10]. Activation of p53 leads to transcrip-
tional up-regulation of various p53 target genes [3]. To engage p53
under these various stress conditions, a complex regulatory net-
work has evolved for precise p53 regulation. This regulatory net-
work prevents accidental p53 activation, which is potentially
lethal to many cell types, but initiates a rapid p53 response when
stress signals are sensed. The key molecule in the p53 regulatory
network is Mdm2, an E3 ubiquitin ligase with potentially onco-
genic activity. Dynamic ﬁne-tuning of the Mdm2-centered net-
work dictates the proper rapidity, intensity, and duration of aFederation of European Biochemi
. Wang).p53 response, resulting in the appropriate biological outcomes
[11].
p53 is modiﬁed by many types of posttranslational modiﬁca-
tions. Among these, ubiquitination by E3 ligases has, perhaps, the
most signiﬁcant impact on p53 biology [12,13]. Many cellular E3
ligases capable of mediating p53 ubiquitination have been identi-
ﬁed. The founding member of HECT domain E3 ligases that target
p53 for degradation is E6AP, a protein that ubiquitinates p53 only
in the presence of the human papillomaviruses E6 protein [14,15].
Mdm2 E3 ligase appears to be the physiological and primary E3 li-
gase regulating p53, and is thus the best studied in the ﬁeld. Sev-
eral recent reviews provide a comprehensive updates on our
current understanding of Mdm2 [8,10,16,17]. This review will fo-
cus on recent advances in the regulation of Mdm2 E3 ligase activity
by MdmX, and the signiﬁcance of MdmX for p53 regulation, as
summarized in Fig. 1.
2. Mdm2-dependent p53 inhibition: canceling transcription
or degrading the protein
Mdm2 was initially discovered as a p53 binding protein that
possesses potent inhibitory effects on p53-mediated transcription
[18]. The crystal structure of an Mdm2 N-terminal fragment bound
with a p53 transactivation domain peptide demonstrated that the
amino acids of p53 involved in binding to the Mdm2 cleft arecal Societies. Open access under CC BY-NC-ND license.
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Fig. 1. Mdm2 and MdmX control p53 stability at multiple levels. (A) p53 and Mdm2 form a well-established autoregulatory feedback loop in which p53 transactivatesMdm2
gene transcription and the subsequent increase in Mdm2 protein inactivates p53. Recently, the MdmX-L isoform has been shown to participate in a similar loop. (B) Mdm2
acting alone mediates monoubiquitination of p53 at multiple sites, facilitating p53 nuclear export to the cytoplasm. Other E3 ligases (such as Pirh2, etc.), or Mdm2 together
with other E4 factors (such as UBE4B) or E4-like molecules (such as Cul4-DDB complex and p300/CBP) can polyubiquitinate p53 leading to its degradation by 26S.
Deubiquitinases such as HAUSP, whose major substrates are ubiquitinated Mdm2 and MdmX, and USP10, whose major substrate is ubiquitinated p53, are involved in
removal of ubiquitin moieties from their corresponding substrates and contribute to p53 stability control. (C) Mdm2/MdmX heterodimers formed via their RING domains
mediate p53 polyubiquitination for efﬁcient proteasomal degradation. Various stress signals trigger MdmX polyubiquitination by Mdm2/MdmX leading to degradation of
MdmX, the activator component of Mdm2/MdmX E3 complexes, resulting in p53 stabilization and activation. Conversely, speciﬁc deubiquitinases exert dynamic regulation
of p53, Mdm2, and/or MdmX by deubiquitinating these three proteins.
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Therefore, Mdm2 binding conceals the transactivation potential of
p53 by forming Mdm2/p53 complexes. Later, it was found that
overexpression of Mdm2 also promotes proteasomal degradation
of p53 [20,21]. Using GST-Mdm2 fusion protein to reconstitute
p53 ubiquitination in vitro, it was demonstrated that Mdm2 is an
E3 ligase and that Mdm2 belongs to the RING family of E3 ligases
[22,23]. Several other p53 E3 ligases have since been identiﬁed.
However, Mdm2 appears to be essential in restricting p53 activity
during embryonic development as demonstrated by mouse genetic
studies [13,24,25]. In addition to p53, Mdm2 E3 ligase has other
substrates such as ribosomal protein L27 that regulates p53 trans-
lation [26]. Importantly, conditional loss of Mdm2 in several adult
tissues causes p53-dependent cell death accompanied by p53 pro-
tein accumulation and activation of p53 target gene expression
[10,16]. Since the p53 binding domain of Mdm2 resides in the N-
terminus while the E3 ligase activity resides in the C-terminus,
mutation of the Mdm2 RING domain allows one to differentiate be-
tween the effects of Mdm2 on inhibiting p53 transcription and the
effects on p53 degradation in vivo. Surprisingly, RING domain
point mutations like Mdm2C462A cause p53-dependent lethality
in a manner similar to complete deletion of the whole Mdm2 gene
[27]. This observation implies that the binding of Mdm2 to the p53
transactivation domain has little effect while the E3 ligase activity
within the RING domain is sufﬁcient to account for Mdm2 medi-
ated p53 inhibition [28]. Subsequent to these discoveries, the
Mdm2 RING domain became the centerpiece of p53 regulation
in vivo.
3. MdmX as a potent activator of Mdm2-dependent p53
degradation in vitro and in vivo
The mechanism underlying Mdm2-dependent p53 degradation
is complicated by the discovery of MdmX, a RING ﬁnger-containinghomolog of Mdm2 [29]. Genetic studies indicate that MdmX is as
essential as Mdm2 for negative regulation of p53 during embryonic
development because MdmX knockout also causes p53-dependent
embryonic lethality in mice [30]. Genetic analysis suggests that
MdmX-mediated p53 inhibition consists of two components, one
that is dependent on Mdm2 and one that is not [31]. Conditional
deletion of Mdm2 causes a signiﬁcant increase in p53 protein lev-
els in MEFs, while conditional deletion of MdmX in an Mdm2 het-
erozygous background causes only a moderate increase in p53
protein levels. This observation has led to the conclusion that
Mdm2 regulates p53 mainly through protein degradation while
MdmX regulates p53 mainly via modulation of its transcriptional
activity [32]. MdmX is a potent inhibitor of p53 transcriptional
activity [29,33]. However, how MdmX contributes to Mdm2-
dependent p53 degradation has remained controversial for many
years. There are several possible reasons for this: (1) Mdm2 was
originally reported to be sufﬁcient for p53 polyubiquitination
in vitro in a concentration-dependent manner [34], suggesting
other factors play only minor roles in the p53 ubiquitination pro-
cess; (2) MdmX has little E3 ligase activity toward p53; (3) MdmX
overexpression in cell culture has generated contradictory results
with regards to p53 ubiquitination and degradation (see reference
in [33]).
MdmX shares low overall similarity with Mdm2 at the level of
amino acid sequence. However, both proteins have a nearly identi-
cal p53 binding domain at their N-terminus and a RING domain at
their C-terminus. A RING domain is a well-established E2-interact-
ing domain that confers E3 ligase activity to RING domain-contain-
ing proteins [35]. However, RING domains can also interact with
RING domains of other proteins thus forming protein heterodimers
[36]. Interestingly, the Mdm2 RING domain was found capable of
interacting with the MdmX RING domain [37]. Although MdmX
does not possess signiﬁcant E3 ligase activity towards p53, MdmX
autoubiquitination does occur in vitro [38,39]. The stimulatory ef-
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onstrated nicely in an in vitro reconstitution system [38,40]. Fur-
thermore, MdmX was shown to promote Mdm2-mediated p53
ubiquitination and degradation through RING–RING interaction
in cell culture systems [41–43]. However, the signiﬁcance of the
MdmX RING domain in Mdm2-dependent p53 degradation re-
mains controversial.
One of our surprising observations was that GST-Mdm2 and
His-tag-Mdm2 behaved differently in an in vitro reconstitution
system [39]. The His-tag-Mdm2 on its own could only mediate
monoubiquitination of p53 at multiple sites, which was in sharp
contrast to the dose-dependent p53 polyubiquitination observed
when using GST-Mdm2. After cleavage of GST from GST-Mdm2,
GST-free Mdm2 was signiﬁcantly compromised in its p53 poly-
ubiquitination activity, and generated an ubiquitin-adduct pattern
reminiscent of monoubiquitination of p53 at multiple sites as re-
ported previously [44]. Inspired by the dimerization property of
GST [45] and the Mdm2–MdmX heterodimers are preferred over
Mdm2 homodimers [37], we reasoned that Mdm2–MdmX hetero-
dimers might be required for robust p53 polyubiquitination. As
predicted by this hypothesis, MdmX activated Mdm2 for p53 poly-
ubiquitination in vitro in a dose dependent manner. When a mix-
ture of recombinant MdmX and Mdm2 proteins was fractionated
by gel ﬁltration and the resulting fractions used as the E3 source
for p53 ubiquitination, a strong E3 ligase activity for p53 polyubiq-
uitination was detected only in one fraction. This fraction coin-
cided with the peak fraction for MdmX and a sub-peak fraction
for Mdm2. This rediscovery of Mdm2 as a monoubiquitin E3 led
to the demonstration that MdmX as an essential activator of
Mdm2 for p53 polyubiquitnation by heterodimerization through
their respective RING domains [39]. These ﬁndings provided a bio-
chemical basis for MdmX-mediated regulation of p53 in vivo [31]
and for the requirement of RING domain in both MdmX and
Mdm2 for efﬁcient p53 ubiquitination and degradation [42].
Given that p53 polyubiquitination is required for proteasomal
degradation and that RING domain-mediated Mdm2/MdmX inter-
action is required for p53 polyubiquitination, it can be predicted
that MdmX RING domain mutations will cause p53-dependent
embryonic lethality in mice. Consistent with this prediction, Yuan’s
and Lozano’s groups recently demonstrated that knock-in of
MdmX RING domain mutants, either a MdmxC462A point muta-
tion or a RING domain deletion, caused a p53-dependent embry-
onic lethality in mice [46,47]. In both cases, the timing of
embryonic lethality is around day-9.5 of gestation, which is similar
to the complete MdmX knockout [30]. The day-9.5 MdmxC462A
mutant embryos manifest massive p53 accumulation associated
with upregulation of p53 downstream genes including p21, bax
and mdm2 [46]. The embryonic lethality can be rescued either by
reduced p53 levels as in the p53 hypomorphic genetic background
(at 15% normal level of p53) or by a genetic background containing
a transcriptionally inactive p53 mutant (p53R172H) [47]. There-
fore, this p53-dependent lethality is caused by two factors: (1) in-
creased p53 protein levels; and (2) transcriptional activity of p53.
Interestingly, when p53 levels are reduced to 15% of normal levels
in hypomorphic p53-expressing MEFs, p53 stability is no longer
under regulation by the Mdm2/MdmX complex [47]. Loss of p53
stability control by the Mdm2/MdmX complex might be the reason
why hypomorphic p53 rescues the embryonic lethality of MdmX
RING mutant mice. If p53 does not accumulate, then p53-depen-
dent lethality will not occur. From biochemical point of view, this
is understandable since the initial substrate concentration will sig-
niﬁcantly affect the kinetics of p53 polyubiquitination catalyzed by
Mdm2/MdmX. The importance of basal p53 levels in determining
p53’s sensitivity to Mdm2/MdmX-mediated regulation may have
additional implications: Mdm2/MdmX regulation permits a basal
level of p53 to exist under non-stressful conditions.4. Biochemical effects of MdmX on p53 ubiquitination
A precedent for a RING–RING heterodimer holoenzyme E3 li-
gase is the BRCA1/BARD1 complex [36]. In contrast to this com-
plex, however, MdmX plays a dual role in the Mdm2/MdmX
heterodimer of being both an activator as well as a substrate of
the E3 ligase activity. This adds an additional layer of complexity
to the p53/Mdm2/MdmX regulatory loop. When there is no p53,
MdmX is efﬁciently ubiquitinated by Mdm2/MdmX. This MdmX-
oriented ubiquitination protects Mdm2 from autoubiquitination-
mediated degradation thus exerting a stabilizing effect on Mdm2
to maintain basal levels. However, when p53 is present, p53 be-
comes the preferential substrate over MdmX in the ternary com-
plex. Moreover, when MdmX concentration exceeds a certain
threshold, excess monomer MdmX might compete with p53 for
polyubiquitination in vitro and stabilizes p53 in vivo [39]. This bio-
chemical evidence may help explain earlier reports that MdmX
overexpression stabilized both p53 and Mdm2 [48–50]. In most
cancer cell lines, MdmX is abundantly expressed due to its consti-
tutive expression and protein stability. Therefore, Mdm2 is the lim-
iting factor in determining the levels of the Mdm2/MdmX
holoenzyme and thus p53 degradation. Thus increasing Mdm2 lev-
els will promote p53 degradation in a dose dependent manner. In
cancer cells where basal levels of MdmX are high, however, further
increases in MdmX will stabilize p53 by functioning as a compet-
itive substrate for polyubiquitination [39,41]. In cases where
MdmX basal levels are low and rate limiting relative to Mdm2,
increasing MdmX expression would be expected to decrease p53
stability by augmenting its polyubiquitination. Thus, the effects
of increasing MdmX expression are context dependent [39]. An-
other alternative mechanism underlying the complex effects of
MdmX relates to the potential effect of MdmX on heterogeneity
of ubiquitin chains in Mdm2-mediated ubiquitination reaction,
which will be discussed later in more details.
Biochemically, how MdmX activates Mdm2 for p53 polyubiqui-
tination is presently not known. In the ubiquitin conjugation sys-
tems, it is usually the E2 ubiqutin conjugating enzymes that
determine the preferred usage of the seven lysine residues within
ubiquitin thereby deﬁning the types of polyubiquitin chains
assembled on substrates. Some E2s such as UBE2K, only form
K48 type polyubiquitin chains, while others such as the UbcH5
family have the potential to form K11, K27, K33, or K48 type of
chains [51]. The E2 enzymes readily form homodimers in solution
and homodimers are sufﬁcient to assemble polyubiquitin chains if
artiﬁcially tethered to a substrate [51]. E3 ligases constrain the E2-
mediated ubiquitin conjugation reaction in two aspects: (a) the
speciﬁc lysine on ubiquitin that is used and (b) the particular
acceptor lysine residue modiﬁed on the substrate [52]. The accep-
tor lysine residues are often located in ﬂexible loops or edges of
secondary structure within substrates. Binding of E3 ligase to sub-
strates restricts their structural ﬂexibility and may also increase
the speciﬁcity of ubiquitin chain types formed on E2 dimers that
are bound to the E3s. How MdmX affects these processes as well
as the processivity of Mdm2-mediated p53 ubiquitination is cur-
rently unknown. One possibility is that MdmX binding might alter
the conformation of p53 or change how the E2 interacts with p53.
The structure of the MdmX–p53 complex has recently been solved
and it indicates that MdmX binding does alter p53 conformation.
This type of conformational change is not observed in Mdm2-
bound p53 [53]. Using GST-Mdm2 and GST-MdmX in an in vitro
system, it was found that Mdm2 alone ubiquitinates lysine resi-
dues in the DNA binding domain of p53 while Mdm2/MdmX ubiq-
uitinates lysine residues in the p53 C-terminus [52]. This may
reﬂect the p53 conformational change induced by MdmX binding.
Another possible mechanism may involve the effects of MdmX
binding on how E2 interacts with p53, as suggested by the crystal
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that have weakened binding activity to UbcH5 [54,55]. The RING
domains of Mdm2 and MdmX adopts a new extended E2 interface
when they form heterodimers [55]. Some Mdm2 mutants are
defective in p53 polyubiquitination due to their weakened E2
interaction. Interestingly, this defect can be rescued by MdmX,
probably by enhancing Mdm2–E2 interaction [39,54,55]. MdmX
also has an unexpected effect on inﬂuencing the ubiquitin chain
types found in p53-ub adducts. The ubiquitin chain type of p53-
ub adducts is K48 when ubiquitinated by GST-Mdm2 alone
whereas it becomes K6, K11, and K48 types when ubiquitinated
by GST-Mdm2/GST-MdmX heterodimers in the presence of
UBE2D3 (UBCH5C) [52]. This heterogeneity of polyubiquitin chain
types catalyzed by Mdm2/MdmX in vitro has been reported previ-
ously [38]. These ﬁndings, if conﬁrmed with GST-free Mdm2 and
MdmX in vitro and in vivo, will raise many new questions. For
example, are K6, K11, K48 ubiquitin-p53 adducts degraded at equal
efﬁciency by the 26S proteasome? What is the ratio of Mdm2
homodimers relative to Mdm2/MdmX heterodimers in cells, and
how does this ratio regulate p53 stability? Does the ratio of
Mdm2 homodimers to Mdm2/MdmX heterodimers change in re-
sponse to stress signals? What are the E2 enzymes for Mdm2 in
cells? Does the Mdm2/MdmX heterodimer use the same or differ-
ent E2 enzymes?
5. Destruction of MdmX for a p53 response
Decoupling the p53/Mdm2 feedback loop is the focal point of
stress signaling to p53. It appears that regulated MdmX degrada-
tion is the key to inactivation of the Mdm2/MdmX E3 ligase during
a p53 response. Several laboratories have observed that DNA dam-
age triggers accelerated MdmX degradation, which causes p53 sta-
bilization. Interestingly, inducible degradation of MdmX is
mediated by Mdm2, or more accurately by Mdm2/MdmX complex,
making it an extremely efﬁcient mechanism for decoupling the
p53/Mdm2 feedback loop through self-destruction [56,57]. Fur-
thermore, this decoupling process is regulated by the upstream
DNA damage signaling kinases ATM/ATR and c-Abl, both well-
established activators of the p53-dependent checkpoint response
[58–62]. The phosphorylation of MdmX by these kinases stimu-
lates recruitment of adaptor protein 14-3-3, promotes MdmX nu-
clear translocation [63,64], and accelerate Mdm2-dependent
MdmX degradation [58,59,65]. The critical role of this regulated
MdmX degradation in the p53 mediated response to DNA damage
has been nicely demonstrated by the attenuated p53 stabilization
in Mdmx3SA knockin MEFs in which the DNA damage kinase phos-
phorylation sites of MdmX are mutated [66]. It appears that there
are two branches of signaling involved in this regulated MdmX
degradation: ATM-dependent phosphorylation of MdmX [58] and
c-Abl-mediated phosphorylation of Mdm2 at three putative sites
that increases Mdm2/MdmX heterodimers formation after DNA
damage [62]. In this case, phosphorylation of both MdmX and
Mdm2 by two upstream kinases acts to switch MdmX as the pref-
erential substrate of Mdm2/MdmX E3 ligase complex after DNA
damage. Notably, it has been shown that ATM-dependent phos-
phorylation disrupt Mdm2 RING domain oligomerization when
cellular protein samples were processed by caspase-3 that releases
a fragment containing the RING domain (aa362–491) of Mdm2 and
analyzed by size exclusion chromatography [67]. However, MdmX
has a same capase-3 site as Mdm2. Therefore, it remains to be
tested how ATM phosphorylation of Mdm2 and MdmX differen-
tially affect formation of Mdm2 homodimers and Mdm2/MdmX
heterodimers in vitro and in vivo at full length protein levels.
In addition to DNA damage, other stress responses also utilize
selective degradation of MdmX as mechanism to activate p53.
Oncogenic growth signals induce expression of tumor suppressorARF, which in turn stabilizes p53 protein by binding and inhibiting
Mdm2-mediated p53 polyubiquitination and degradation [68]. The
N-terminal 20 amino acids of ARF bind to the acidic domain of
Mdm2 and inhibit p53 ubiquitination in vitro [69]. In contrast to
the effects on p53, ARF binding selectively promotes ubiquitination
and degradation of MdmX [56]. In cells, ARF binding induces a sec-
ond-site interaction between the central region of Mdm2 and
MdmX, resulting in increased MdmX ubiquitination and subse-
quent degradation [70]. Hence, rather than inhibiting the intrinsic
E3 ligase activity of Mdm2/MdmX, ARF acts to switch the substrate
preference to MdmX thus sparing p53. Conceivably, the loss of ARF
in cancer cells has dual negative effects on p53 via MdmX stabiliza-
tion: (a) inhibition of p53 transactivation by MdmX and (b)
enhancing p53 degradation by increasing Mdm2/MdmX E3 com-
plex formation.
Similarly to ARF, several ribosomal proteins (RPs) including
RPL11, RPL23 and RPL5 bind to the acidic domain of Mdm2. As a
result, they also inhibit Mdm2-mediated p53 ubiquitination in
cells [8]. Loss of homeostasis in ribosome biogenesis leads to an in-
crease in free ribosomal proteins, which in turn serve as an emer-
gency call to activate the p53 stress response pathway. Selective
MdmX degradation is also involved in the p53 response to ribo-
somal stress. Perturbation of ribosome biogenesis by low doses
of actinomycin D causes a signiﬁcant decrease in MdmX protein.
Ribosomal stress introduced by overexpressing RPL11 causes a de-
crease in MdmX protein accompanied by increased Mdm2-depen-
dent MdmX ubiquitination and degradation [71]. In this case,
ribosomal proteins are also substrate switchers like ARF, thus alert-
ing the cell to ribosomal stress by activating p53.
Nucleolar protein PICT-1 is a tumor suppressor candidate
whose low expression in gliomas and ovarian cancer is correlated
with high malignant progression. PICT-1 was initially found to sta-
bilize PTEN by their physical interaction. Surprisingly, knockout of
pict-1 leads to release of RPL11 from nucleolus, which in turn acti-
vates a p53 response by inhibiting Mdm2 E3 ligase activity [72]. In
a recent report, 5S rRNA was found to stabilize MdmX protein. 5S
rRNA binds to the RING ﬁnger of MdmX and inhibits MdmX ubiq-
uitination by Mdm2 [73]. RNAi knockdown of 5S rRNA does not
perturb ribosome assembly, nor does it affect p53 ubiquitination
in vitro or p53 abundance in cells, but it does increase p53 depen-
dent transcription [73]. Therefore, 5S rRNA might play a role to
maintain constitutive levels of MdmX without serving as substrate
switcher for Mdm2/MdmX.
Another signiﬁcant advance in the ﬁeld is the recent identiﬁca-
tion of a functional p53 responsive promoter in the MdmX gene.
This makes MdmX another component of the Mdm2/p53 feedback
loop. This p53 responsive promoter (P2) was found in the ﬁrst in-
tron of the human MdmX (HdmX) gene and is functional in a p53-
depndent manner under various conditions [74,75]. This promoter
directs production of a novel HdmX transcript that is translated
into a long version of HdmX (Hdmx-L) with an extra 18 amino
acids at the N-terminus. Interestingly, HdmX-L has a weakened
binding afﬁnity for p53 and thus has little effect on p53 transcrip-
tional activity. However, HdmX-L is just as efﬁcient as HdmX in
Mdm2-mediated p53 ubiquitination and plays an important role
in bringing p53 to basal levels after stress mediated activation [74].
6. Deubiquitinases as regulators of the Mdm2/MdmX E3
complex
Mdm2/MdmX E3 ligase as well as p53 can be regulated by
deubiquitinases. HAUSP (USP7) was the ﬁrst deubiquitinase identi-
ﬁed for p53 and can stabilize p53 through its deubiquitination [76].
However, somatic knockout of HAUSP or embryonic knockout of
HAUSP causes p53 stabilization rather than destabilization. This
phenomenon is associated with loss of Mdm2 expression in HAUSP
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maintaining Mdm2 stability [77,78]. It is not surprising that HAUSP
also forms a complex with Mdm2 [79]. However, it is surprising
that HAUSP also binds MdmX and stabilizes MdmX through
deubiquitination. MdmX protein is essentially below detectable
levels in HCT116/HAUSP/ cells [80]. Therefore, p53 stabilization
in HAUSP knockout cells might originate from loss of MdmX result-
ing in destabilization of Mdm2 protein and thus a decrease in
Mdm2/MdmX E3-mediated p53 degradation. The HAUSP–MdmX
interaction is disrupted by DNA damage suggesting a possible
involvement of HAUSP in Mdm2/MdmX downregulation after
DNA damage [80]. In contrast to HAUSP, USP2a was found to bind
and speciﬁcally deubiquitinate Mdm2 and MdmX but not p53
[81,82]. Knockdown of USP2a stabilizes p53 but causes decreased
expression of Mdm2 and MdmX. Treatment with DNA damaging
agent cisplatin causes downregulation of USP2a in cells, which
may contribute to downregulation of MdmX/Mdm2 and the even-
tual p53 stabilization in DNA damage response [82]. In contrast to
HAUSP and USP2a, USP10 appears to speciﬁcally deubiquitinate
p53 because knockdown of USP10 in HCT116/p53/ cells does
not cause reduction in Mdm2. Importantly, USP10 can be phos-
phorylated by ATM resulting its stabilization and nuclear translo-
cation, a phenomenon opposite to what occurs to USP2a in DNA
damaged cells [83]. Like USP10, USP42 is another p53-speciﬁc
deubiquitinase and plays a role in DNA damage-induced p53 sta-
bilization [84]. Taken together, the action of these deubiquitinases
antagonizes the action of Mdm2/MdmX and other E3 ligases,
which makes p53 regulation more dynamic in a context-depen-
dent manner.7. Other p53 E3 ligases
Although Mdm2/MdmX work together through RING–RING
interactions to regulate p53 degradation, mouse studies suggest
that Mdm2 and MdmX are differentially involved in p53 regula-
tion. Knockout of Mdm2 and knock-in of an Mdm2 RING mutant
kill the embryos at an earlier developmental stage (day-5.5 to
7.5) [24,27,85], while knockout of MdmX or knock-in of an MdmX
RING mutant kills the embryos at day-9.5 [30,46,47]. These results
suggest that at an earlier developmental stage, Mdm2 itself is suf-
ﬁcient to completely inhibit p53 through its RING domain without
need of MdmX. Possible mechanisms underlying this stage-depen-
dent p53 inhibition might be: (1) Mdm2-mediated monoubiquiti-
nation in the absence of MdmX drives p53 nuclear export, which
is sufﬁcient for inactivation of p53 nuclear activity; and/or (2)
other existing E3 ligases or E4 factors complete the ubiquitin-
dependent degradation process of the exported p53 in the cyto-
plasm [13]. However, at the later stage of development, the role
of MdmX in Mdm2/MdmX is irreplaceable by other factors [11].
Since Mdm2 is the catalytic component of Mdm2/MdmX E3 ligase,
loss of Mdm2 will be phenotypically equivalent to loss of Mdm2/
MdmX as far as p53 polyubiquitination is concerned. However,
the opposite is not true: loss of MdmX causes milder p53 stabiliza-
tion than loss of Mdm2 [32]. This suggests that either Mdm2-med-
iated monoubiquitination of p53 plays a role in p53 degradation
with aid of other E3 ligases, or Mdm2 homodimers that are formed
in the absence of MdmX contributes to the process. In this context,
discovery of cellular factors that facilitate Mdm2 homodimeriza-
tion in the absence of MdmX will be the key to understanding
the biochemical entities of the p53 death-insulting E3 ligases in
cells. Equally important is the need for more careful analysis of
other p53 E3 ligases such as Pirh2, Cul4–DDB1 E3 complexes,
COP1, ARF-BP1, Synoviolin, CBP/p300(E4), UBE4B and SCF(Jfk) in
well-deﬁned systems with regard to cell type and stress speciﬁc
p53 responses. Further study of these E3 ligases will help betterunderstand the mechanisms of p53 degradation in the absence of
MdmX [86–91].
With regard to p53 polyubiquitination, there is confusion in
interpreting p53 polyubiquitination versus multiple monoubiquiti-
nation in the literature. Using wild type and methylated ubiquitins
in an in vitro p53 ubiquitination reaction by Mdm2, Lai et al. dem-
onstrated that seven distinct new p53 bands were recognizable on
an SDS–PAGE gel, indicating seven primary ubiquitination sites on
p53 [44]. A polyubiquitin chain of 4-ubiquitin length can serve a
degradation signal for 26S proteasomes [92]. Based on the calcula-
tion, the degradable polyubiquitinated p53 species should appear
in a smearing pattern above 138 kDa on SDS–PAGE gels. Therefore,
we suggest that polyubiquitinated p53 region should be labeled at
least above 138 kDa on a SDS–PAGE gel in future studies. In addi-
tion to p53 polyubiquitination by the Mdm2/MdmX complex,
Cul4–DDB1 complexes, UBE4B and p300/CBP are worthy of discus-
sion. Cullin4 (Cul4)-containing E3 ligases are multi-subunit E3
complexes consisting of Cullin4A or 4B (scaffold), DDB1 (linker
subunit), WD40 proteins (substrate receptor) and ROC1 (RING-do-
main subunit). Cul4–DDB1complexes are involved in nucleotide
excision repair and are responsible for DNA damage-induced deg-
radation of CDT1, a DNA replication licensing factor, in the pres-
ence of L2DTL/CDT2 and PCNA [93]. Cul4 scaffolds interact with
more than 50 WD40 proteins and thus may target numerous sub-
strates for ubiquitin-dependent regulation [94]. Interestingly,
Cul4–DDB1-containing E3 ligases are capable of mediating p53
polyubiquitination in an Mdm2-dependent manner [95]. Both
p53 and Mdm2 can be detected in the Cul4–DDB1 E3 complexes
and knockdown of each component of these E3 complexes cause
p53 accumulation in several cell lines. DNA damage or UV irradia-
tion leads to dissociation of p53 from Cul4–DDB1 E3 complexes
implying that this E3 activity may be involved in maintaining fast
turnover of p53 in unstressed cells. Surprisingly, the Cul4A-speciﬁc
immunoprecipitates from Mdm2/p53 double-null MEFs lacks this
activity in vitro, suggesting that Cul4–DDB1 complexes do not pos-
sess intrinsic E3 ligase activity for p53 polyubiquitination. How-
ever, the Cul4A-speciﬁc immunoprecipitates from wild type
MEFs or Mdm2-overexpressing Mdm2/p53 double-null MEFs can
promote extensive p53 polyubiquitination in vitro, indicating
Mdm2-dependence of this process. Therefore, Cul4–DDB1 com-
plexes act as E4 factors in this case. It was proposed that PCNA is
the bridging molecule that brings Mdm2 into the Cul4–DDB1 com-
plexes. However, how signaling events regulate Mdm2–PCNA
interaction and whether the RING domain of Mdm2 is required
in this process merit further investigation. Although deletion of
DDB1, the linker component of Cul4-based E3 ligases, in brain
causes p53-dependent apoptosis, thus supporting potential roles
of this E3 family in p53 regulation in vivo, it is yet to be determined
whether this is a direct effect of the Cul4–DDB1 E3 complexes or an
indirect effect of DNA damage-signaling observed in DDB-null tis-
sues [96].
Similar to Cul4–DDB1 complexes, the mammalian homolog of
yeast ubiquitin chain assembly factor UBE4B has been shown to
promote p53 polyubiquitination and cellular degradation in the
presence of Mdm2 [97]. In fact, UBE4B is a member of U-box E3 li-
gase family [98], possessing intrinsic U-box-dependent E3 ligase
activity toward p53. However, p53 polyubiquitination by UbE4B it-
self is low but is greatly enhanced in the presence of Mdm2. Knock-
down of UBE4B reduced polyubiquitinated p53 species in cells was
accompanied by accumulation of multi-monoubiquitinated p53,
indicating a major role of UBE4B as an E4 factor in the p53 ubiqui-
tination process. Of note, the N-terminal part of p300 and CBP acet-
yltransferases has been shown to possess similar activity to UBE4B
[90,99]. p300 or CBP speciﬁc immunoprecipitates strongly pro-
motes p53 polyubiquitination of Mdm2–p53 complex in vitro.
Moreover, knockdown of either p300 or CBP results in p53 accu-
X. Wang, X. Jiang / FEBS Letters 586 (2012) 1390–1396 1395mulation in cells. Interestingly, this E4 activity only exists in the
cytosolic CBP complex but not in the nuclear CBP complex. This no-
vel activity assigns a new role to p300/CBP in p53 regulation,
opposing its nuclear acetyltransferase effect on p53 through acet-
ylation of p53 c-terminal lysine residues [100,101]. Many interest-
ing questions arise from this observation. For example, is this E4
activity intrinsic to p300/CBP proteins? Are the putative Zn-ﬁn-
ger-like domains a structural requirement of p300/CBP for this
E4 activity? Is this activity regulated by DNA damage signaling or
by associated factors in cytoplasm? Is RING domain of Mdm2 re-
quired in this process? Future investigation using recombinant
CBP/p300 proteins rather than CBP/p300-immunoprecipitates in
an in vitro system will provide answers to these questions.
As summarized in Fig. 1, recent evidence from in vitro biochem-
ical analysis and in vivo mouse models has established an essential
role of the MdmX RING domain in p53 inhibition through control-
ling p53 stability. Several p53 signal transduction pathways utilize
MdmX downregulation to launch a p53 response. Other E3 ligases
and E4 factors contribute to p53 stability control when Mdm2 is
not sufﬁcient for p53 polyubiquitination. Actions of different
deubiquitinases enable a dynamic regulation of the p53 levels. Fur-
ther investigation of RING–RING interaction of Mdm2 and MdmX
should lead to better understanding of Mdm2/MdmX E3 ligase reg-
ulation. Undoubtedly, studies on functional compensation of
Mdm2 by other E3 ligases will reveal more speciﬁc details of the
p53 degradation process in cells.
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